Precision medicine approaches to lung adenocarcinoma with concomitant MET and HER2 amplification

[1]  Jeffrey W. Clark,et al.  Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer. , 2015, Cancer discovery.

[2]  W. Park,et al.  HER2 as a novel therapeutic target for cervical cancer , 2015, Oncotarget.

[3]  H. Seol,et al.  Patient-Derived Xenografts from Non–Small Cell Lung Cancer Brain Metastases Are Valuable Translational Platforms for the Development of Personalized Targeted Therapy , 2014, Clinical Cancer Research.

[4]  A. Yoshizawa,et al.  HER2 status in lung adenocarcinoma: a comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations. , 2014, Lung cancer.

[5]  Steven J. M. Jones,et al.  Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.

[6]  A. López-Rivas,et al.  Activated ERBB2/HER2 licenses sensitivity to apoptosis upon endoplasmic reticulum stress through a PERK-dependent pathway. , 2014, Cancer research.

[7]  Alfonso Valencia,et al.  Integrated Next-Generation Sequencing and Avatar Mouse Models for Personalized Cancer Treatment , 2014, Clinical Cancer Research.

[8]  S. Peters,et al.  Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Yoon-La Choi,et al.  Development and characterization of a bladder cancer xenograft model using patient‐derived tumor tissue , 2013, Cancer science.

[10]  H. Woo,et al.  Patient-specific orthotopic glioblastoma xenograft models recapitulate the histopathology and biology of human glioblastomas in situ. , 2013, Cell reports.

[11]  Wei Zhou,et al.  ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors , 2012, Molecular Cancer Therapeutics.

[12]  Razelle Kurzrock,et al.  Novel Therapeutic Targets in Non-small Cell Lung Cancer , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[13]  Jeffrey W. Clark,et al.  Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[14]  Y. Jeon,et al.  High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[15]  I. Okamoto.  Epidermal growth factor receptor in relation to tumor development: EGFR‐targeted anticancer therapy , 2010, The FEBS journal.

[16]  K. Eguchi,et al.  Impact of HER2 Gene and Protein Status on the Treatment Outcome of Cisplatin-Based Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[17]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Validation of the Proposals for Revision of the T, N, and M Descriptors and Consequent Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[18]  Joon-Oh Park,et al.  MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.

[19]  Elisa Rossi,et al.  Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Elisabeth Brambilla,et al.  The 2004 World Health Organization classification of lung tumors. , 2005, Seminars in roentgenology.

[21]  J. Downward,et al.  Identification and characterization of a new oncogene derived from the regulatory subunit of phosphoinositide 3‐kinase , 1998, The EMBO journal.

[22]  L. Urban,et al.  Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement. , 2014, Lung cancer.

[23]  Somasekar Seshagiri,et al.  Somatic mutations lead to an oncogenic deletion of met in lung cancer. , 2006, Cancer research.

[24]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.